Wen Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wen Lu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Dongzhen Yu
Department of Otolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Lingkang Dong
Department of Otolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications- Qiang Ma
Department of Otolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Wenqi Dong
Department of Otolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publicationsYumeng Jiang
Department of Otolaryngology Head & Neck Surgery, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publicationsZhuangzhuang Li
Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 12 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12623-12635
Global, regional, and national trends in 34 cancers through a novel burden–quality-of-care framework: a cross-sectional study
Background: Current unidimensional cancer evaluation systems limit precise cancer control. This study establishes a novel burden–quality framework that integrates disease burden and quality-of-care index (QCI) to better assess cancer management effectiveness globally. Methods: The QCI was derived by principal component analysis of six standardized indicators using the Global Burden of Disease data (1990–2021). A four-quadrant framework integrated QCI with disease burden to classify 34 cancers across 204 countries/regions. The sociodemographic index (SDI) and gender disparity ratios (GDR) were used to assess inequalities. Results: Substantial heterogeneity exists in the burden and QCI across 34 cancers. Highly fatal cancers such as TBL cancers (tracheal, bronchus, and lung cancers) and pancreatic cancers are persistently trapped in a “high burden-low quality” dilemma. In contrast, high-burden breast cancer and low-burden thyroid cancer demonstrate superior QCI, though the latter may carry overtreatment risks. Socioeconomic factors have a profound influence on intervention equity, with SDI exhibiting a strong positive correlation with QCI ( r = 0.90, P < 0.001) but a significant negative correlation with GDR ( r = −0.71, P < 0.001). Notably, the trend of QCI improvement and overall reduction in cancer burden is asynchronous: high-survival cancers and high-SDI regions showed slow QCI gains, middle-SDI regions exhibited substantial increases, while low-SDI areas remained persistently disadvantaged. Demographic disparities further exacerbated these inequities – older populations bore a disproportionate disease burden yet achieved the fastest QCI improvements, whereas adolescent groups maintained high baseline quality but stagnated in progress. Additionally, gender disparities were pervasive, with females receiving better-quality care for most cancers and across most regions. Conclusion: This multidimensional burden–quality framework shifts cancer evaluation from singular evaluation to precision intervention. It emphasizes: (1) optimizing resources for high-burden–low-quality cancers, (2) avoiding overtreatment in low-burden cancers, and (3) reducing inequities linked to socioeconomic disparities and vulnerable groups (especially elderly and male patients). This research provides a foundation for precise and equitable global cancer control.
- 12 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12623-12635
Open AccessGlobal, regional, and national trends in 34 cancers through a novel burden–quality-of-care framework: a cross-sectional study
Background: Current unidimensional cancer evaluation systems limit precise cancer control. This study establishes a novel burden–quality framework that integrates disease burden and quality-of-care index (QCI) to better assess cancer management effectiveness globally. Methods: The QCI was derived by principal component analysis of six standardized indicators using the Global Burden of Disease data (1990–2021). A four-quadrant framework integrated QCI with disease burden to classify 34 cancers across 204 countries/regions. The sociodemographic index (SDI) and gender disparity ratios (GDR) were used to assess inequalities. Results: Substantial heterogeneity exists in the burden and QCI across 34 cancers. Highly fatal cancers such as TBL cancers (tracheal, bronchus, and lung cancers) and pancreatic cancers are persistently trapped in a “high burden-low quality” dilemma. In contrast, high-burden breast cancer and low-burden thyroid cancer demonstrate superior QCI, though the latter may carry overtreatment risks. Socioeconomic factors have a profound influence on intervention equity, with SDI exhibiting a strong positive correlation with QCI ( r = 0.90, P < 0.001) but a significant negative correlation with GDR ( r = −0.71, P < 0.001). Notably, the trend of QCI improvement and overall reduction in cancer burden is asynchronous: high-survival cancers and high-SDI regions showed slow QCI gains, middle-SDI regions exhibited substantial increases, while low-SDI areas remained persistently disadvantaged. Demographic disparities further exacerbated these inequities – older populations bore a disproportionate disease burden yet achieved the fastest QCI improvements, whereas adolescent groups maintained high baseline quality but stagnated in progress. Additionally, gender disparities were pervasive, with females receiving better-quality care for most cancers and across most regions. Conclusion: This multidimensional burden–quality framework shifts cancer evaluation from singular evaluation to precision intervention. It emphasizes: (1) optimizing resources for high-burden–low-quality cancers, (2) avoiding overtreatment in low-burden cancers, and (3) reducing inequities linked to socioeconomic disparities and vulnerable groups (especially elderly and male patients). This research provides a foundation for precise and equitable global cancer control.
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41227
Analysis of the clinical features of neurocristopathy-related hearing loss and how these relate to outcomes after cochlear implantation
The clinical features of neurocristopathy-related hearing loss, and the correlation between these features and patient improvements after cochlear implantation (CI) are unknown. This study enrolled 16 children with sensorineural hearing loss due to four types of neurocristopathies, Waardenburg syndrome (WS), Noonan syndrome (NS), Kabuki syndrome (KS), and CHARGE syndrome (CS), who underwent CI. Neurodevelopmental assessment was conducted using the Gesell Developmental Schedules, ear development was evaluated using temporal bone computed tomography, and the post-CI auditory nerve response was assessed via neural response telemetry. Auditory performance was evaluated using the categories of the auditory performance scale. Genetic features were examined using whole-exome sequencing. WS/NS Groups achieved excellent auditory-speech outcomes (CAP_3 year/SIR_3 year: WS 7.3/4.0 n = 3, NS 8.0/4.0 n = 1), using Categories of Auditory Performance (CAP) and Speech Intelligibility Rating (SIR), with minimal impact from SOX10 (WS) or PTPN11 (NS) mutations on neurodevelopment. CS Group showed poor recovery (CAP_3 year/SIR_3 year: 3.3/1.8 n = 3) due to CHD7-related cochlear nerve dysplasia and central auditory deficits, Gesell_mean showed a significant positive correlation with CAP_1 year (ρ = 0.83 n = 6 p = 0.042), CAP_3 year was significantly correlated with both implantation CI_age_mon and Gesell_mean independently (ρ = 1.0, n = 3, p < 0.001). Non-CS Groups(WS/NS/KS)showed older CI_age_mon predicted higher 1-year SIR (ρ = 0.77 n = 10 p = 0.009), while structural abnormalities (abnormal_sum) trended toward worse 3-year SIR (ρ=-0.79 n = 5). The integration of genetic, ear structure, and neurodevelopmental assessments can assist in clinical decision making for CI.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41227
Open AccessAnalysis of the clinical features of neurocristopathy-related hearing loss and how these relate to outcomes after cochlear implantation
The clinical features of neurocristopathy-related hearing loss, and the correlation between these features and patient improvements after cochlear implantation (CI) are unknown. This study enrolled 16 children with sensorineural hearing loss due to four types of neurocristopathies, Waardenburg syndrome (WS), Noonan syndrome (NS), Kabuki syndrome (KS), and CHARGE syndrome (CS), who underwent CI. Neurodevelopmental assessment was conducted using the Gesell Developmental Schedules, ear development was evaluated using temporal bone computed tomography, and the post-CI auditory nerve response was assessed via neural response telemetry. Auditory performance was evaluated using the categories of the auditory performance scale. Genetic features were examined using whole-exome sequencing. WS/NS Groups achieved excellent auditory-speech outcomes (CAP_3 year/SIR_3 year: WS 7.3/4.0 n = 3, NS 8.0/4.0 n = 1), using Categories of Auditory Performance (CAP) and Speech Intelligibility Rating (SIR), with minimal impact from SOX10 (WS) or PTPN11 (NS) mutations on neurodevelopment. CS Group showed poor recovery (CAP_3 year/SIR_3 year: 3.3/1.8 n = 3) due to CHD7-related cochlear nerve dysplasia and central auditory deficits, Gesell_mean showed a significant positive correlation with CAP_1 year (ρ = 0.83 n = 6 p = 0.042), CAP_3 year was significantly correlated with both implantation CI_age_mon and Gesell_mean independently (ρ = 1.0, n = 3, p < 0.001). Non-CS Groups(WS/NS/KS)showed older CI_age_mon predicted higher 1-year SIR (ρ = 0.77 n = 10 p = 0.009), while structural abnormalities (abnormal_sum) trended toward worse 3-year SIR (ρ=-0.79 n = 5). The integration of genetic, ear structure, and neurodevelopmental assessments can assist in clinical decision making for CI.
- Open Access
- 26 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (10) , 1-11
Global burden and prevalence of otitis media-induced hearing loss in children: 32-year study
Background Hearing loss in children has become a pressing public health issue, with otitis media (OM) being a leading cause. This study aims to comprehensively assess the prevalence and burden of OM-induced hearing loss in children. Methods Data from the Global Burden of Disease (GBD) database were used. We evaluated the Age-standardized Prevalence Rates (ASPR), Age-standardized Years Lived with Disability rates (ASYR), and Estimated Annual Percentage Changes (EAPC) over the past 32 years. The analysis included stratification, correlation analysis, and projections. Results From 1990 to 2021, the global prevalence of OM-induced hearing loss in children under 15 years increased from 31.18 million cases to 34.71 million cases, representing an 11.32% increase. The ASPR slightly decreased from 1793.38 to 1725.39 per 100,000 children, with an EAPC of -0.13. Boys had a higher prevalence and burden compared to girls, and the highest ASPR and ASYR were observed in children aged 5–9 years. Regions with higher Socio-Demographic Index (SDI) showed significant reductions in both prevalence and burden, while low-middle SDI regions bore a heavier burden, with ASPR 1.81 times higher and cases number 6.08 times higher than high SDI regions. Additionally, East Asia showed the largest decrease, while South Asia had the highest ASPR. Conclusion Although the global burden of OM-induced hearing loss has improved, South Asia and low-middle SDI regions continue to face a significant burden, with insufficient healthcare resources likely being a major issue. Additionally, continuing to advance pneumococcal vaccination and other preventive measures is equally crucial for alleviating this burden.
- 26 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (10) , 1-11
Open AccessGlobal burden and prevalence of otitis media-induced hearing loss in children: 32-year study
Background Hearing loss in children has become a pressing public health issue, with otitis media (OM) being a leading cause. This study aims to comprehensively assess the prevalence and burden of OM-induced hearing loss in children. Methods Data from the Global Burden of Disease (GBD) database were used. We evaluated the Age-standardized Prevalence Rates (ASPR), Age-standardized Years Lived with Disability rates (ASYR), and Estimated Annual Percentage Changes (EAPC) over the past 32 years. The analysis included stratification, correlation analysis, and projections. Results From 1990 to 2021, the global prevalence of OM-induced hearing loss in children under 15 years increased from 31.18 million cases to 34.71 million cases, representing an 11.32% increase. The ASPR slightly decreased from 1793.38 to 1725.39 per 100,000 children, with an EAPC of -0.13. Boys had a higher prevalence and burden compared to girls, and the highest ASPR and ASYR were observed in children aged 5–9 years. Regions with higher Socio-Demographic Index (SDI) showed significant reductions in both prevalence and burden, while low-middle SDI regions bore a heavier burden, with ASPR 1.81 times higher and cases number 6.08 times higher than high SDI regions. Additionally, East Asia showed the largest decrease, while South Asia had the highest ASPR. Conclusion Although the global burden of OM-induced hearing loss has improved, South Asia and low-middle SDI regions continue to face a significant burden, with insufficient healthcare resources likely being a major issue. Additionally, continuing to advance pneumococcal vaccination and other preventive measures is equally crucial for alleviating this burden.
- Top Cited PapersOpen Access
- 19 February 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-20
Global trends and risk factors of laryngeal cancer: a systematic analysis for the Global Burden of Disease Study (1990–2021)
This study aimed to explore the epidemiological trends of laryngeal cancer (LC) using the 2021 Global Burden of Disease (GBD) data. We analyzed the global LC incidence, deaths, disability-adjusted life years (DALYs), and risk factors from 1990 to 2021. We evaluated trends using the annual percentage change (EAPC) and examined variations and associations in LC burden across regions, sociodemographic index (SDI) categories, and age groups. In 2021, the global age-standardized incidence rate (ASIR) for LC was 2.293 (95% UI: 2.133–2.466), the age-standardized death rate (ASDR) was 1.35 (1.259–1.449), and the age-standardized DALYs rate was 35.803 (33.294–38.538). The EAPCs for ASIR, ASDR, and age-standardized DALYs were -1.089, -1.659, and -1.816, respectively. The ASIR was positively correlated with the SDI (R = 0.32, P < 0.05). The Caribbean had the highest ASDR (2.69) and second-highest EAPC of ASDR (-0.151). Tobacco accounted for 66.46% of global LC deaths, with a decreasing trend over the last 30 years (R = -1, P < 0.05). Conversely, occupational exposure among females showed an increasing trend (R = 0.61, P < 0.05). The reduction in death rate for the 80–89 years age group was nearly twice as high in the high SDI regions as in the low SDI regions (21.89% vs. 11.92%). From 1990 to 2021, global LC incidence, deaths, and DALYs decreased, although regional disparities persisted. Death rates remain high in economically disadvantaged regions, especially among the elderly and females with occupational risk. Continued efforts to control tobacco use, develop equitable screening programs, and enhance occupational safety are crucial for addressing global disparities in LC outcomes.
- 19 February 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-20
Top Cited PapersOpen AccessGlobal trends and risk factors of laryngeal cancer: a systematic analysis for the Global Burden of Disease Study (1990–2021)
This study aimed to explore the epidemiological trends of laryngeal cancer (LC) using the 2021 Global Burden of Disease (GBD) data. We analyzed the global LC incidence, deaths, disability-adjusted life years (DALYs), and risk factors from 1990 to 2021. We evaluated trends using the annual percentage change (EAPC) and examined variations and associations in LC burden across regions, sociodemographic index (SDI) categories, and age groups. In 2021, the global age-standardized incidence rate (ASIR) for LC was 2.293 (95% UI: 2.133–2.466), the age-standardized death rate (ASDR) was 1.35 (1.259–1.449), and the age-standardized DALYs rate was 35.803 (33.294–38.538). The EAPCs for ASIR, ASDR, and age-standardized DALYs were -1.089, -1.659, and -1.816, respectively. The ASIR was positively correlated with the SDI (R = 0.32, P < 0.05). The Caribbean had the highest ASDR (2.69) and second-highest EAPC of ASDR (-0.151). Tobacco accounted for 66.46% of global LC deaths, with a decreasing trend over the last 30 years (R = -1, P < 0.05). Conversely, occupational exposure among females showed an increasing trend (R = 0.61, P < 0.05). The reduction in death rate for the 80–89 years age group was nearly twice as high in the high SDI regions as in the low SDI regions (21.89% vs. 11.92%). From 1990 to 2021, global LC incidence, deaths, and DALYs decreased, although regional disparities persisted. Death rates remain high in economically disadvantaged regions, especially among the elderly and females with occupational risk. Continued efforts to control tobacco use, develop equitable screening programs, and enhance occupational safety are crucial for addressing global disparities in LC outcomes.
- Open Access
- 6 August 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (8) , e14896
Electroencephalography microstate alterations reflect potential double‐edged cognitive adaptation in Ménière's disease
Purpose: To explore the microstate characteristics and underlying brain network activity of Ménière's disease (MD) patients based on high‐density electroencephalography (EEG), elucidate the association between microstate dynamics and clinical manifestation, and explore the potential of EEG microstate features as future neurobiomarkers for MD.Methods: Thirty‐two patients diagnosed with MD and 29 healthy controls (HC) matched for demographic characteristics were included in the study. Dysfunction and subjective symptom severity were assessed by neuropsychological questionnaires, pure tone audiometry, and vestibular function tests. Resting‐state EEG recordings were obtained using a 256‐channel EEG system, and the electric field topographies were clustered into four dominant microstate classes (A, B, C, and D). The dynamic parameters of each microstate were analyzed and utilized as input for a support vector machine (SVM) classifier to identify significant microstate signatures associated with MD. The clinical significance was further explored through Spearman correlation analysis.Results: MD patients exhibited an increased presence of microstate class C and a decreased frequency of transitions between microstate class A and B, as well as between class A and D. The transitions from microstate class A to C were also elevated. Further analysis revealed a positive correlation between equilibrium scores and the transitions from microstate class A to C under somatosensory challenging conditions. Conversely, transitions between class A and B were negatively correlated with vertigo symptoms. No significant correlations were detected between these characteristics and auditory test results or emotional scores. Utilizing the microstate features identified via sequential backward selection, the linear SVM classifier achieved a sensitivity of 86.21% and a specificity of 90.61% in distinguishing MD patients from HC.Conclusions: We identified several EEG microstate characteristics in MD patients that facilitate postural control yet exacerbate subjective symptoms, and effectively discriminate MD from HC. The microstate features may offer a new approach for optimizing cognitive compensation strategies and exploring potential neurobiological markers in MD.
- 6 August 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (8) , e14896
Open AccessElectroencephalography microstate alterations reflect potential double‐edged cognitive adaptation in Ménière's disease
Purpose: To explore the microstate characteristics and underlying brain network activity of Ménière's disease (MD) patients based on high‐density electroencephalography (EEG), elucidate the association between microstate dynamics and clinical manifestation, and explore the potential of EEG microstate features as future neurobiomarkers for MD.Methods: Thirty‐two patients diagnosed with MD and 29 healthy controls (HC) matched for demographic characteristics were included in the study. Dysfunction and subjective symptom severity were assessed by neuropsychological questionnaires, pure tone audiometry, and vestibular function tests. Resting‐state EEG recordings were obtained using a 256‐channel EEG system, and the electric field topographies were clustered into four dominant microstate classes (A, B, C, and D). The dynamic parameters of each microstate were analyzed and utilized as input for a support vector machine (SVM) classifier to identify significant microstate signatures associated with MD. The clinical significance was further explored through Spearman correlation analysis.Results: MD patients exhibited an increased presence of microstate class C and a decreased frequency of transitions between microstate class A and B, as well as between class A and D. The transitions from microstate class A to C were also elevated. Further analysis revealed a positive correlation between equilibrium scores and the transitions from microstate class A to C under somatosensory challenging conditions. Conversely, transitions between class A and B were negatively correlated with vertigo symptoms. No significant correlations were detected between these characteristics and auditory test results or emotional scores. Utilizing the microstate features identified via sequential backward selection, the linear SVM classifier achieved a sensitivity of 86.21% and a specificity of 90.61% in distinguishing MD patients from HC.Conclusions: We identified several EEG microstate characteristics in MD patients that facilitate postural control yet exacerbate subjective symptoms, and effectively discriminate MD from HC. The microstate features may offer a new approach for optimizing cognitive compensation strategies and exploring potential neurobiological markers in MD.
- 1 August 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 308 (2) , e230457
Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization
Background Hepatocellular carcinomas (HCCs) can be divided into proliferative and nonproliferative types, which may have implications for outcomes after conventional transarterial chemoembolization (cTACE). Biopsy to identify proliferative HCC is not routinely performed before cTACE. Purpose To develop and validate a predictive model for identifying proliferative HCCs using CT imaging features and to compare therapeutic outcomes between predicted proliferative and nonproliferative HCCs after cTACE according to this model. Materials and Methods This retrospective multicenter study included adults with HCC who underwent liver resection or cTACE between August 2013 and December 2020. A CT-based predictive model for identifying proliferative HCCs was developed and externally validated in a cohort that underwent resection. Diagnostic performance was calculated for the model. Thereafter, patients in the cTACE cohort were stratified into groups with predicted proliferative or nonproliferative HCCs according to the model. The primary outcome was overall survival (OS), and the secondary outcomes were tumor response rate and progression-free survival (PFS). These were compared between the two groups with use of the χ2 test and the log-rank test. Results A total of 1194 patients (1021 men; mean age, 54 years ± 12 [SD]; median follow-up time, 29.1 months) were included. The predictive model, named the SMARS score, incorporated lobulated shape, mosaic architecture, α-fetoprotein levels, rim arterial phase hyperenhancement, and satellite lesions. The area under the receiver operating characteristic curve for the SMARS score was 0.83 for the training cohort and 0.80 for the validation cohort. According to the SMARS score, patients with predicted proliferative HCCs (n = 114) had lower tumor response rate (48% vs 71%; P < .001) and worse PFS (6.6 months vs 12.4 months; P < .001) and OS (14.4 months vs 38.7 months; P < .001) than those with nonproliferative HCCs (n = 263). Conclusion The predictive model demonstrated good performance for identifying proliferative HCCs. According to the SMARS score, patients with predicted proliferative HCCs have worse prognosis than those with predicted nonproliferative HCCs after cTACE. © RSNA, 2023 Supplemental material is available for this article.
- 1 August 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 308 (2) , e230457
Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization
Background Hepatocellular carcinomas (HCCs) can be divided into proliferative and nonproliferative types, which may have implications for outcomes after conventional transarterial chemoembolization (cTACE). Biopsy to identify proliferative HCC is not routinely performed before cTACE. Purpose To develop and validate a predictive model for identifying proliferative HCCs using CT imaging features and to compare therapeutic outcomes between predicted proliferative and nonproliferative HCCs after cTACE according to this model. Materials and Methods This retrospective multicenter study included adults with HCC who underwent liver resection or cTACE between August 2013 and December 2020. A CT-based predictive model for identifying proliferative HCCs was developed and externally validated in a cohort that underwent resection. Diagnostic performance was calculated for the model. Thereafter, patients in the cTACE cohort were stratified into groups with predicted proliferative or nonproliferative HCCs according to the model. The primary outcome was overall survival (OS), and the secondary outcomes were tumor response rate and progression-free survival (PFS). These were compared between the two groups with use of the χ2 test and the log-rank test. Results A total of 1194 patients (1021 men; mean age, 54 years ± 12 [SD]; median follow-up time, 29.1 months) were included. The predictive model, named the SMARS score, incorporated lobulated shape, mosaic architecture, α-fetoprotein levels, rim arterial phase hyperenhancement, and satellite lesions. The area under the receiver operating characteristic curve for the SMARS score was 0.83 for the training cohort and 0.80 for the validation cohort. According to the SMARS score, patients with predicted proliferative HCCs (n = 114) had lower tumor response rate (48% vs 71%; P < .001) and worse PFS (6.6 months vs 12.4 months; P < .001) and OS (14.4 months vs 38.7 months; P < .001) than those with nonproliferative HCCs (n = 263). Conclusion The predictive model demonstrated good performance for identifying proliferative HCCs. According to the SMARS score, patients with predicted proliferative HCCs have worse prognosis than those with predicted nonproliferative HCCs after cTACE. © RSNA, 2023 Supplemental material is available for this article.
- Open Access
- 2 February 2023
- Published by Elsevier in Academic Radiology
- Vol. 30, S176-S184
MRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
- 2 February 2023
- Published by Elsevier in Academic Radiology
- Vol. 30, S176-S184
Open AccessMRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
- Open Access
- 1 March 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 197, 114904
Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy
- 1 March 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 197, 114904
Open AccessTrehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy